Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACRVNASDAQ:ACXPNASDAQ:ALGSNASDAQ:ESLA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACRVAcrivon Therapeutics$1.17+1.7%$1.94$1.09▼$10.16$36.69M1.88225,842 shs431,432 shsACXPAcurx Pharmaceuticals$0.40+0.5%$0.38$0.30▼$3.33$9.39M-1.37165,106 shs106,125 shsALGSAligos Therapeutics$5.50-3.0%$6.22$3.76▼$46.80$33.63M2.76199,911 shs75,983 shsESLAEstrella Immunopharma$1.04+4.0%$0.96$0.63▼$3.23$37.61M0.4185,803 shs4,970 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACRVAcrivon Therapeutics+1.74%+1.74%-41.50%-78.88%-86.35%ACXPAcurx Pharmaceuticals+0.45%+3.36%+3.36%-48.89%-84.31%ALGSAligos Therapeutics-3.00%-5.82%+2.61%-70.48%-66.62%ESLAEstrella Immunopharma+4.00%+8.45%+1.97%-29.73%+2.46%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACRVAcrivon Therapeutics3.0165 of 5 stars4.52.00.00.01.72.50.6ACXPAcurx Pharmaceuticals2.7616 of 5 stars3.55.00.00.02.71.70.0ALGSAligos Therapeutics3.4074 of 5 stars3.51.00.04.80.61.70.6ESLAEstrella Immunopharma1.485 of 5 stars3.53.00.00.00.01.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACRVAcrivon Therapeutics 3.00Buy$17.711,414.04% UpsideACXPAcurx Pharmaceuticals 3.00Buy$8.001,900.00% UpsideALGSAligos Therapeutics 3.00Buy$70.001,172.73% UpsideESLAEstrella Immunopharma 3.00Buy$16.001,438.46% UpsideCurrent Analyst Ratings BreakdownLatest ACXP, ACRV, ALGS, and ESLA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/16/2025ACRVAcrivon TherapeuticsJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold5/15/2025ACRVAcrivon TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$10.00 ➝ $9.005/15/2025ACXPAcurx PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy$8.005/5/2025ACRVAcrivon TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$6.005/4/2025ACRVAcrivon TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy3/31/2025ALGSAligos TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$70.00 ➝ $70.003/26/2025ACRVAcrivon TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight3/26/2025ACRVAcrivon TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$22.00 ➝ $19.003/19/2025ACXPAcurx PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.00 ➝ $12.003/11/2025ALGSAligos TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$75.00 ➝ $70.00(Data available from 5/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACRVAcrivon TherapeuticsN/AN/AN/AN/A$5.38 per shareN/AACXPAcurx PharmaceuticalsN/AN/AN/AN/A$0.34 per shareN/AALGSAligos Therapeutics$3.27M10.28N/AN/A$30.65 per share0.18ESLAEstrella ImmunopharmaN/AN/AN/AN/A$0.12 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACRVAcrivon Therapeutics-$60.39M-$2.22N/AN/AN/AN/A-47.95%-43.73%8/12/2025 (Estimated)ACXPAcurx Pharmaceuticals-$14.58M-$0.70N/AN/AN/AN/A-392.36%-223.78%8/8/2025 (Estimated)ALGSAligos Therapeutics-$87.68M-$17.51N/AN/AN/A-1,283.19%-114.34%-64.58%8/5/2025 (Estimated)ESLAEstrella Immunopharma-$7.31M-$0.26N/A∞N/AN/A-195.77%-157.28%N/ALatest ACXP, ACRV, ALGS, and ESLA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025ACRVAcrivon Therapeutics-$0.57-$0.51+$0.06-$0.51N/AN/A5/12/2025Q1 2025ACXPAcurx Pharmaceuticals-$0.14-$0.11+$0.03-$0.11N/AN/A5/6/2025Q1 2025ALGSAligos Therapeutics-$2.80-$2.11+$0.69-$2.11$0.33 million$0.31 million3/27/2025Q4 2024ACRVAcrivon Therapeutics-$0.69-$0.60+$0.09-$0.60N/AN/A3/17/2025Q4 2024ACXPAcurx Pharmaceuticals-$0.18-$0.16+$0.02-$0.16N/AN/A3/10/2025Q4 2024ALGSAligos Therapeutics-$2.63-$13.08-$10.45-$13.08$0.43 million$0.63 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACRVAcrivon TherapeuticsN/AN/AN/AN/AN/AACXPAcurx PharmaceuticalsN/AN/AN/AN/AN/AALGSAligos TherapeuticsN/AN/AN/AN/AN/AESLAEstrella ImmunopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACRVAcrivon TherapeuticsN/A12.7512.75ACXPAcurx PharmaceuticalsN/A1.801.80ALGSAligos TherapeuticsN/A3.813.81ESLAEstrella ImmunopharmaN/A0.750.75Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACRVAcrivon Therapeutics71.62%ACXPAcurx Pharmaceuticals11.53%ALGSAligos Therapeutics60.43%ESLAEstrella Immunopharma0.35%Insider OwnershipCompanyInsider OwnershipACRVAcrivon Therapeutics8.50%ACXPAcurx Pharmaceuticals29.60%ALGSAligos Therapeutics8.75%ESLAEstrella Immunopharma55.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACRVAcrivon Therapeutics5831.36 million28.49 millionNot OptionableACXPAcurx Pharmaceuticals323.48 million11.99 millionOptionableALGSAligos Therapeutics906.11 million3.27 millionNo DataESLAEstrella ImmunopharmaN/A36.17 million16.24 millionNot OptionableACXP, ACRV, ALGS, and ESLA HeadlinesRecent News About These CompaniesEstrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Buy Rating With a Price Target of $14.00 From CB Capital PartnersMarch 5, 2025 | finance.yahoo.comEstrella Immunopharma completes first dose cohort in STARLIGHT trialFebruary 21, 2025 | markets.businessinsider.comEstrella Immunopharma Completes First Dose Cohort in STARLIGHT-1 Trial and Receives Approval to Initiate Higher Dose CohortFebruary 21, 2025 | businesswire.comEstrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) Receives Buy Rating with a 12-Month Price Target of $16.00 from D. Boral CapitalFebruary 19, 2025 | businesswire.comD. Boral Capital Initiates Coverage of Estrella Immunopharma (ESLA) with Buy RecommendationFebruary 19, 2025 | msn.comSpotlight On US Penny Stocks: Estrella Immunopharma And Two Others To ConsiderNovember 19, 2024 | uk.finance.yahoo.comEstrella Immunopharma (NASDAQ:ESLA) Stock, Short Interest ReportOctober 11, 2024 | benzinga.comEstrella Immunopharma (NASDAQ:ESLA) Stock Quotes, Forecast and News SummaryOctober 11, 2024 | benzinga.comEstrella Immunopharma Inc (ESLA) Stock: Unveiling Its Hidden StrengthsSeptember 30, 2024 | bovnews.comEstrella Immunopharma Shares Rise on Lymphoma Patient's Treatment ResponseSeptember 28, 2024 | marketwatch.comEstrella Immunopharma Achieves Complete Response in First Patient Treated with CD19- Redirected ARTEMIS® T-cellsSeptember 27, 2024 | finance.yahoo.comEstrella Immunopharma, Inc. (ESLAW)August 24, 2024 | uk.finance.yahoo.comWhy Estrella Immunopharma Inc (NASDAQ:ESLA) Stock Jumped 140.22% in Last Month?July 27, 2024 | bovnews.comESLA Stock Earnings: Estrella Immunopharma Reported Results for Q3 2024May 20, 2024 | investorplace.comEntheon Biomedical Corp. (ENTBD)March 7, 2024 | finance.yahoo.comEstrella Immunopharma Approves $1 Million Stock Buyback ProgramFebruary 1, 2024 | msn.comWhy DatChat Shares Are Trading Lower By Around 33%; Here Are 20 Stocks Moving PremarketJanuary 17, 2024 | msn.comEstrella Immunopharma Inc (ESLA)November 23, 2023 | uk.investing.comEstrella Immunopharma, Inc. (ESLA)November 3, 2023 | finance.yahoo.comEstrella Immunopharma Inc ESLANovember 1, 2023 | morningstar.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeACXP, ACRV, ALGS, and ESLA Company DescriptionsAcrivon Therapeutics NASDAQ:ACRV$1.17 +0.02 (+1.74%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$1.17 0.00 (0.00%) As of 05/23/2025 07:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in Phase II clinical trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response, or DDR, pathways; and ACR-2316, a dual WEE1/PKMYT1 inhibitor. Acrivon Therapeutics, Inc. was incorporated in 2018 and is based in Watertown, Massachusetts.Acurx Pharmaceuticals NASDAQ:ACXP$0.40 +0.00 (+0.45%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$0.40 -0.01 (-1.25%) As of 05/23/2025 07:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.Aligos Therapeutics NASDAQ:ALGS$5.50 -0.17 (-3.00%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$5.44 -0.06 (-1.09%) As of 05/23/2025 07:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.Estrella Immunopharma NASDAQ:ESLA$1.04 +0.04 (+4.00%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$1.03 -0.01 (-0.96%) As of 05/23/2025 04:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/19 - 05/23 Trade Desk Silences Critics; Recovery Looks Poised to Continue Booz Allen Hamilton Earnings: 3 Bullish Signals for BAH Stock Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain These ETFs Provide Easy Exposure to Growing International Markets Advance Auto Parts Jumps on Surprise Earnings Beat Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
